Amendment to Warrant to Purchase Common Stock between Actinium Pharmaceuticals, Inc. and Amrosan LLC (November 8, 2018)

Summary

Actinium Pharmaceuticals, Inc. and Amrosan LLC have agreed to amend a previous warrant agreement originally dated December 17, 2012. This amendment extends the period during which Amrosan LLC can exercise its right to purchase common stock under the warrant, moving the expiration date to February 21, 2022. All other terms of the original warrant remain unchanged. The amendment is effective as of November 8, 2018.

EX-4.1 2 f10q0918ex4-1_actinium.htm AMENDMENT TO ACTINIUM PHARMACEUTICALS, INC. WARRANT TO PURCHASE COMMON STOCK, DATED NOVEMBER 8, 2018 ISSUED TO AMOSAN LLC.

Exhibit 4.1

AMENDMENT
TO
ACTINIUM PHARMACEUTICALS, INC. WARRANT TO PURCHASE COMMON STOCK

Pursuant to Section 9(a) of the Warrant to Purchase Common Stock of (the “Warrant”) of Actinium Pharmaceuticals, Inc. (the “Company”), originally dated December 17, 2012, issued to Amrosan LLC in the amount of 375,556 warrant shares, the Board of Directors of the Company has duly adopted a resolution approving this Amendment to the Warrant to extend the term of the Warrant to February 21, 2022 as follows:

Section 1 of the Warrant is hereby amended to read in its entirety as follows:

“Term of Warrant. Subject to the terms and conditions set forth herein, this Warrant shall be exercisable, in whole or in part, during the term commencing (“Issuance Date”) December 17, 2012 (the “Warrant Issue Date”), and ending at 5:00 p.m., Eastern Time on February 21, 2022 and shall be void thereafter.”

All other terms and provisions of the Warrant shall remain unchanged and in full force and effect as written.

IN WITNESS WHEREOF, this Amendment to the Warrant is made effective this 8^th day of November, 2018.

		ACTINIUM PHARMACEUTICALS, INC.

		By:	/s/ David Nicholson
		Name:	David Nicholson
		Title:	Chairman Compensation Committee